Nidufexor

Nidufexor
Identifiers
	IUPAC name 4-{[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl}benzoic acid;
CAS Number	1773489-72-7;
PubChem CID	118063735;
ChemSpider	57617776;
UNII	CJ1PL0TE6J;
ChEMBL	ChEMBL4297626;
CompTox Dashboard (EPA)	DTXSID801336678 ;
Chemical and physical data
Formula	C27H22ClN3O4
Molar mass	487.94 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O;
	InChI InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34); Key:JYTIXGYXBIBOMN-UHFFFAOYSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Nidufexor (LMB-763) is a drug which acts as a partial agonist of the farnesoid X receptor (FXR). It has reached Phase II clinical trials for the treatment of diabetic nephropathy and nonalcoholic steatohepatitis.^[1]^[2]

References

^ Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, et al. (April 2020). "Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis". Journal of Medicinal Chemistry. 63 (8): 3868–3880. doi:10.1021/acs.jmedchem.9b01621. PMID 31940200.
^ Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E (June 2020). "Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)". Expert Opinion on Investigational Drugs. 29 (6): 623–632. doi:10.1080/13543784.2020.1763302. PMID 32552182. S2CID 219911969.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, et al. (April 2020). "Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis". Journal of Medicinal Chemistry. 63 (8): 3868–3880. doi:10.1021/acs.jmedchem.9b01621. PMID 31940200.

[2] Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E (June 2020). "Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)". Expert Opinion on Investigational Drugs. 29 (6): 623–632. doi:10.1080/13543784.2020.1763302. PMID 32552182. S2CID 219911969.

[1]

[2]

v t e FXRTooltip Farnesoid X receptor and LXRTooltip liver X receptor modulators
FXRTooltip Farnesoid X receptor	Agonists: Bile acids Cafestol Chenodeoxycholic acid Cilofexor Fexaramine GW-4064 Ivermectin Nidufexor Obeticholic acid Tropifexor Antagonists: Guggulsterone
LXRTooltip Liver X receptor	Agonists: 22R-Hydroxycholesterol 24S-Hydroxycholesterol 27-Hydroxycholesterol Abequolixron Cholestenoic acid DMHCA GW-3965 Hypocholamide T-0901317 Antagonists: Efavirenz Larsucosterol
See also Receptor/signaling modulators

See also

References